PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of
HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in
HER2-overexpressing breast cancers may contribute to the aggressive phenotype observed in
HER2-positive breast cancer. New therapeutics targeting VEGF and/or its receptors may enhance
the efficacy of trastuzumab monotherapy.
This trial will investigate the safety and efficacy of combined HER2 and VEGF inhibition.